Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Conditions: Esophageal Neoplasms; Lung Neoplasms; Mesothelioma; Thymus Neoplasms; Neoplasms, Germ Cell and Embryonal Intervention: Drug: Mithramycin Sponsor: National Cancer Institute (NCI) Recruiting - verified July 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Cancer | Cancer & Oncology | Carcinoma | Embryonal Carcinoma | Mesothelioma | Research | Sarcomas | Stem Cell Therapy | Stem Cells